C-reactive protein and other markers of inflammation in hemodialysis patients

author

  • Behzad Heidari
Abstract:

Background: Hemodialysis patients are at greater risk of cardiovascular disease. Higher than expected cardiovascular morbidity and mortality in this population has been attributed to dislipidemia as well as inflammation. The causes of inflammation in hemodialysis patients are multifactorial. Several markers were used for the detection of inflammatory reaction in patients with chronic renal disease. These markers can be used for the prediction of future cardiovascular events. Among the several parameters of inflammatory markers, serum, CRP is well known and its advantages for the detection of inflammation and its predictor ability has been evaluated in several studies. This review addressed the associated factors and markers of inflammation in hemodialysis patients. In addition, their ability in predicting future atherosclerosis and effect of treatment has been reviewed. However, this context particularly in using CRP as a prediction marker of inflammation and morbidity requires further studies.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

c-reactive protein and other markers of inflammation in hemodialysis patients

background: hemodialysis patients are at greater risk of cardiovascular disease. higher than expected cardiovascular morbidity and mortality in this population has been attributed to dislipidemia as well as inflammation. the causes of inflammation in hemodialysis patients are multifactorial. several markers were used for the detection of inflammatory reaction in patients with chronic renal dise...

full text

C-reactive protein and other markers of inflammation in hemodialysis patients.

Hemodialysis patients are at greater risk of cardiovascular disease. Higher than expected cardiovascular morbidity and mortality in this population has been attributed to dislipidemia as well as inflammation. The causes of inflammation in hemodialysis patients are multifactorial. Several markers were used for the detection of inflammatory reaction in patients with chronic renal disease. These m...

full text

The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a condition associated with inflammation in lungs and airways. The impacts of inflammatory process is not limited to respiratory system but extend to extrapulmonary organs with resultant complications involving endocrine, metabolic and cardiovascular systems. The extent and severity of inflammation may be partly estimated by serum measurement of s...

full text

association between serum c- reactive protein levels and other important predictive markers of outcome in copd

c-reactive protein (crp) is an acute-phase protein synthesized predominantly by the hepatocytes in response to tissue damage or inflammation. levels of acute-phase proteins rise rapidly, during infection and after injury. we take up the study to correlate serum crp levels with other important predictive markers of outcome in copd. patient with stable copd (no exacerbation in the last two months...

full text

the importance of c-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease

chronic obstructive pulmonary disease (copd) is a condition associated with inflammation in lungs and airways. the impacts of inflammatory process is not limited to respiratory system but extend to extrapulmonary organs with resultant complications involving endocrine, metabolic and cardiovascular systems. the extent and severity of inflammation may be partly estimated by serum measurement of s...

full text

Differential effects of E and droloxifene on C-reactive protein and other markers of inflammation in healthy postmenopausal women.

Although increased levels of C-reactive protein have been linked to E therapy, the significance of this finding and whether it occurs with the selective ER modulators are unknown. Thirty-five healthy postmenopausal women were enrolled in a placebo-controlled, two-period cross-over design trial to evaluate the effects of 0.625 mg oral conjugated E and 60 mg droloxifene, a structural analog of ta...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 4  issue None

pages  611- 616

publication date 2013-01

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023